Tesamorelin
TesamorelinCreate a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Tesamorelin.
Reduces visceral abdominal fat in clinical studies of HIV‑associated lipodystrophy
Stimulates endogenous growth hormone release and increases IGF‑1 levels
Decreases hepatic fat content in some controlled trials
May reduce elevated triglyceride levels in affected patients
Lowers waist circumference and abdominal girth measurements
Targets visceral fat while generally preserving subcutaneous fat
Associated with improvements in liver enzymes (eg, ALT) in some studies
Used as a targeted treatment for HIV‑related central fat accumulation
This peptide's combination-safety and interaction data below always stays visible, regardless of membership.
Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.
Discussions
Community discussions are coming soon.